Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 11, 2015, Pages 2037-2045

  Kwak, Min Sun ^a,b   Yu, Su Jong ^a   Yoon, Jung Hwan ^a   Lee, Sung Hee ^a   Lee, Soo Mi ^a   Lee, Jeong Hoon ^a   Kim, Yoon Jun ^a   Lee, Hyo Suk ^a   Kim, Chung Yong ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University Hospital Healthcare System Gangnam Center   (South Korea)

Author keywords

Apoptosis; Doxorubicin; Flavopiridol; Hepatocellular carcinoma; Hypoxia

Indexed keywords

DOXORUBICIN; FLAVOPIRIDOL; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CELL CYCLE PROTEIN; FLAVONOID; HEXOKINASE; HIF1A PROTEIN, MOUSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C3H/HE MOUSE; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; BIOSYNTHESIS; C3H MOUSE; CANCER TRANSPLANTATION; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENETICS; LIVER NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG SYNERGISM; FLAVONOIDS; HEXOKINASE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; PIPERIDINES; PROTEIN KINASE INHIBITORS; TUMOR BURDEN;

EID: 84951567371     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1990-6     Document Type: Article

References (28)

1. Akiba J, Ogasawara S, Kawahara A, Nishida N, Sanada S, Moriya F, Kuwano M, Nakashima O, Yano H (2008) N-myc downstream regulated gene 1 (NDRG1)/Cap43 enhances portal vein invasion and intrahepatic metastasis in human hepatocellular carcinoma. Oncol Rep 20:1329–1335
2. Asghar U, Meyer T (2012) Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol 56:686–695. doi:10.1016/j.jhep.2011.07.031
3. Bagi CM, Gebhard DF, Andresen CJ (2012) Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 24:563–574. doi:10.1097/MEG.0b013e328350916f
4. Beal SL (1984) Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab Rev 15:173–193. doi:10.3109/03602538409015064
5. Budak-Alpdogan T, Chen B, Warrier A, Medina DJ, Moore D, Bertino JR (2009) Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma. Clin Cancer Res 15:1232–1240. doi:10.1158/1078-0432.CCR-08-0810
6. Cao H, Phan H, Yang LX (2012) Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32:1379–1386
7. Chua MS, Sun H, Cheung ST, Mason V, Higgins J, Ross DT, Fan ST, So S (2007) Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod Pathol 20:76–83. doi:10.1038/modpathol.3800711
8. Fan L, Song B, Sun G, Ma T, Zhong F, Wei W (2013) Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells. PLoS ONE 8:e62627. doi:10.1371/journal.pone.0062627
9. Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127:S35–S50
10. Gladyshev VN, Liu A, Novoselov SV, Krysan K, Sun QA, Kryukov VM, Kryukov GV, Lou MF (2001) Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. J Biol Chem 276:30374–30380. doi:10.1074/jbc.M100020200
11. Jung EU, Yoon JH, Lee YJ, Lee JH, Kim BH, Yu SJ, Myung SJ, Kim YJ, Lee HS (2010) Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett 298:9–15. doi:10.1016/j.canlet.2010.05.020
12. Kim W, Yoon JH, Kim JR, Jang IJ, Bang YJ, Kim YJ, Lee HS (2009) Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma. Cancer Chemother Pharmacol 64:497–507. doi:10.1007/s00280-008-0897-1
13. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483
14. Li W, Fan J, Bertino JR (2001) Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Cancer Res 61:2579–2582
15. Lillig CH, Lonn ME, Enoksson M, Fernandes AP, Holmgren A (2004) Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc Natl Acad Sci U S A 101:13227–13232. doi:10.1073/pnas.0401896101
16. Melotte V, Qu X, Ongenaert M, van Criekinge W, de Bruine AP, Baldwin HS, van Engeland M (2010) The N-myc downstream regulated gene (NDRG) family: diverse functions, multiple applications. FASEB J 24:4153–4166. doi:10.1096/fj.09-151464
17. Motwani M, Sirotnak FM, She Y, Commes T, Schwartz GK (2002) Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res 62:3950–3955
18. Newcomb EW (2004) Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs 15:411–419
19. Richard C, Matthews D, Duivenvoorden W, Yau J, Wright PS, Th’ng JP (2005) Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clin Cancer Res 11:3523–3529. doi:10.1158/1078-0432.CCR-04-2507
20. Wall NR, O’Connor DS, Plescia J, Pommier Y, Altieri DC (2003) Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63:230–235
21. Xiang QF, Zhang DM, Wang JN, Zhang HW, Zheng ZY, Yu DC, Li YJ, Xu J, Chen YJ, Shang CZ (2014) Cabozantinib reverses multidrug resistance of human hepatoma HepG2/adr cells by modulating the function of P-glycoprotein. Liver Int. doi:10.1111/liv.12524
22. Yamashita YI, Shimada M, Hasegawa H, Minagawa R, Rikimaru T, Hamatsu T, Tanaka S, Shirabe K, Miyazaki JI, Sugimachi K (2001) Electroporation-mediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61:1005–1012
23. Yan X, Chua MS, Sun H, So S (2008) N-Myc down-regulated gene 1 mediates proliferation, invasion, and apoptosis of hepatocellular carcinoma cells. Cancer Lett 262:133–142. doi:10.1016/j.canlet.2007.12.010
24. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ (2005) A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532–1538. doi:10.1093/jnci/dji315
25. Yu SJ, Yoon JH, Yang JI, Cho EJ, Kwak MS, Jang ES, Lee JH, Kim YJ, Lee HS, Kim CY (2012) Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr 44:101–115. doi:10.1007/s10863-012-9416-5
26. Zhai S, Senderowicz AM, Sausville EA, Figg WD (2002) Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36:905–911
27. Zhou J, Zheng W, Cao L, Liu M, Han F, Li A (2010) Antiangiogenic tumor treatment: noninvasive monitoring with contrast pulse sequence imaging for contrast-enhanced grayscale ultrasound. Acad Radiol 17:646–651. doi:10.1016/j.acra.2010.01.008
28. Zhou J, Wan B, Liu XM, Li R, Wang Y, Yu L (2012) MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 427:581–586. doi:10.1016/j.bbrc.2012.09.101